Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant erythropoietin in patients on CAPD. A rationale for treatment

Contrib Nephrol. 1989:76:112-20; discussion 120-1. doi: 10.1159/000417887.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anemia / complications
  • Anemia / drug therapy
  • Biological Availability
  • Clinical Trials as Topic
  • Erythropoietin / administration & dosage
  • Erythropoietin / blood
  • Erythropoietin / pharmacokinetics*
  • Female
  • Humans
  • Injections, Intraperitoneal
  • Injections, Intravenous
  • Injections, Subcutaneous
  • Kidney Diseases / complications
  • Kidney Diseases / therapy
  • Male
  • Middle Aged
  • Peritoneal Dialysis, Continuous Ambulatory*

Substances

  • Erythropoietin